The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient MiceReportar como inadecuado


The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice


The Effect of Low-Dose Proteasome Inhibition on Pre-Existing Atherosclerosis in LDL Receptor-Deficient Mice - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1

Medizinische Klinik für Kardiologie und Angiologie, Charité–Universitätsmedizin Berlin, Campus Mitte, 10117 Berlin, Germany

2

Experimental and Clinical Research Center, a Joint Cooperation between the Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany

3

DZHK, German Center for Cardiovascular Disease, Partner Site Berlin, 10115 Berlin, Germany





*

Author to whom correspondence should be addressed.



Academic Editor: Nobuhiro Nakamura

Abstract Dysfunction of the ubiquitin-proteasome system UPS has been implicated in atherosclerosis development. However, the nature of UPS dysfunction has been proposed to be specific to certain stages of atherosclerosis development, which has implications for proteasome inhibition as a potential treatment option. Recently, low-dose proteasome inhibition with bortezomib has been shown to attenuate early atherosclerosis in low-density lipoprotein receptor-deficient LDLR−-− mice. The present study investigates the effect of low-dose proteasome inhibition with bortezomib on pre-existing advanced atherosclerosis in LDLR−-− mice. We found that bortezomib treatment of LDLR−-− mice with pre-existing atherosclerosis does not alter lesion burden. Additionally, macrophage infiltration of aortic root plaques, total plasma cholesterol levels, and pro-inflammatory serum markers were not influenced by bortezomib. However, plaques of bortezomib-treated mice exhibited larger necrotic core areas and a significant thinning of the fibrous cap, indicating a more unstable plaque phenotype. Taking recent studies on favorable effects of proteasome inhibition in early atherogenesis into consideration, our data support the hypothesis of stage-dependent effects of proteasome inhibition in atherosclerosis. View Full-Text

Keywords: atherosclerosis; proteasome inhibition; inflammation atherosclerosis; proteasome inhibition; inflammation





Autor: Nicola Wilck 1,2,3,* , Mandy Fechner 1, Cristian Dan 1, Verena Stangl 1,3, Karl Stangl 1,3 and Antje Ludwig 1,3

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados